These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32234756)

  • 1.
    Sinn M; Sinn BV; Treue D; Keilholz U; Damm F; Schmuck R; Lohneis P; Klauschen F; Striefler JK; Bahra M; Bläker H; Bischoff S; Pelzer U; Oettle H; Riess H; Budczies J; Denkert C
    Clin Cancer Res; 2020 Jul; 26(14):3732-3739. PubMed ID: 32234756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
    Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
    Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
    J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
    Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
    Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
    Chikhladze S; Lederer AK; Kousoulas L; Reinmuth M; Sick O; Fichtner-Feigl S; Wittel UA
    World J Surg Oncol; 2019 Nov; 17(1):185. PubMed ID: 31706323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
    Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
    Postlewait LM; Ethun CG; Kooby DA; Sarmiento JM; Chen Z; Staley CA; Brutcher E; Adsay V; El-Rayes B; Maithel SK
    J Surg Oncol; 2016 Sep; 114(3):336-41. PubMed ID: 27501338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
    JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
    Hoyer K; Hablesreiter R; Inoue Y; Yoshida K; Briest F; Christen F; Kakiuchi N; Yoshizato T; Shiozawa Y; Shiraishi Y; Striefler JK; Bischoff S; Lohneis P; Putter H; Blau O; Keilholz U; Bullinger L; Pelzer U; Hummel M; Riess H; Ogawa S; Sinn M; Damm F
    EBioMedicine; 2021 Apr; 66():103327. PubMed ID: 33862582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
    Striefler JK; Sinn M; Pelzer U; Jühling A; Wislocka L; Bahra M; Sinn BV; Denkert C; Dörken B; Oettle H; Riess H; Bläker H; Lohneis P
    Pathol Res Pract; 2016 Aug; 212(8):726-34. PubMed ID: 27461834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
    Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
    Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
    Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
    Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y
    Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?
    Parikh AA; Maiga A; Bentrem D; Squires MH; Kooby DA; Maithel SK; Weber SM; Cho CS; Katz M; Martin RC; Scoggins CR; Sutton J; Ahmad SA; Abbott DE; Carr J; Kim HJ; Yakoub D; Idrees K; Merchant N
    J Am Coll Surg; 2016 Apr; 222(4):448-56. PubMed ID: 26895735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.
    Sinn M; Denkert C; Striefler JK; Pelzer U; Stieler JM; Bahra M; Lohneis P; Dörken B; Oettle H; Riess H; Sinn BV
    Br J Cancer; 2014 Nov; 111(10):1917-23. PubMed ID: 25314063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
    Fraunhoffer N; Hammel P; Conroy T; Nicolle R; Bachet JB; Harlé A; Rebours V; Turpin A; Ben Abdelghani M; Mitry E; Biagi J; Chanez B; Bigonnet M; Lopez A; Evesque L; Lecomte T; Assenat E; Bouché O; Renouf DJ; Lambert A; Monard L; Mauduit M; Cros J; Iovanna J; Dusetti N
    Ann Oncol; 2024 Sep; 35(9):780-791. PubMed ID: 38906254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
    Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
    Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
    Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.